The biotech has signed a non-dilutive funding deal with Oberland Capital as it awaits an FDA ruling on its spinocerebellar ...

Oberland Capital Management is pumping some new life into Biohaven, striking a unique investment deal worth up to $600 ...

Shares of Biohaven ( BHVN 5.24%) are surging on Monday. The company's stock was up about 8% as of midday trading and had ...

Biohaven will use the money to bankroll commercial preparations for the spinocerebellar ataxia drug candidate troriluzole, ...

Biohaven Ltd. (BHVN) shares rise premarket as it secures up to $600 million investment from Oberland Capital. Cash reserves ...

US biotech Biohaven last week received a commitment from Oberland Capital to invest up to $600 million in the company. Also, ...

We recently published a list of Jim Cramer Recently Talked About These 15 Stocks. In this article, we are going to take a ...

Biohaven Ltd. on Monday announced that New York-based Oberland Capital has agreed to invest up to $600 million in the New ...

Currently under review in the U.S. for a rare genetic disorder, the drug is seen by some investors as critical to Biohaven’s ...

Biohaven Ltd. (NYSE: BHVN) (Biohaven or the Company), a global clinical-stage biopharmaceutical company focused on the ...

EDT Biohaven (BHVN) down 12% to $20.60 after pulling European applicationStay Ahead of the Market: Discover outperforming stocks and ...

Shares of Biohaven (NYSE: BHVN) are surging on Monday. The company's stock was up about 8% as of midday trading and had climbed as much as 10% earlier in the day. The move comes as the S&P 500 ...